Skip to Main Content

“You come at the king, you best not miss.”
— Omar Little in “The Wire”

Keytruda is the immunotherapy king. In the U.S., the Merck anti-PD1 checkpoint inhibitor is approved to treat 16 cancers and has 26 indications overall. Sales were $11 billion in 2019 and $6.7 billion through the first half of this year. Keytruda is not only the most successful cancer drug ever developed, but it ranks among the best medicines ever.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!